SHANGHAI, Sept. 29, 2025 -- Smartee Denti-Technology today announced that Professor Gang Shen, its Chief Scientist and Executive President of TaiKang ByBo Dental, has once again been named to the World's Top 2% Scientists list, compiled by Stanford University in partnership with Elsevier. This marks the third consecutive year Prof. Shen has earned this prestigious recognition. Notably, he was honored in both the Career-Long Impact and Single-Year Impact categories, highlighting his long-term global impact and pioneering contributions to orthodontics. Now in its eighth edition,
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") and Health Hope Pharma ("HHP") granting Gilead the exclusive rights to develop and commercialize encequidar. Orascovery™ is an innovative oral drug delivery proprietary platform owned by Hanmi that enables the conversion of injectable medicines into oral
Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SHANGHAI, Sept. 29, 2025 -- Viva Biotech announced today that it has been honored with Frost & Sullivan's 2025 APAC Technology Innovation Leadership recognition in the Integrated Intelligent Drug Discovery industry. As Frost & Sullivan's top honor, the award recognizes outstanding achievements in driving transformative efficiencies in preclinical research and developm
런던, 로마, 스위스 추크, 2025년 9월 29일 -- 글로벌 메이저 제약회사 루팡(Lupin Limited)((BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN))이 29일 지분 100%를 보유한 자회사 나노미(Nanomi B.V.)를 통해 글로벌 헬스케어 전문 투자사 GHO 캐피털 파트너스(GHO Capital Partners LLP)로부터 비쥬파마(VISUfarma B.V.)를 인수하는 계약을 체결했다고 발표했다. 루팡은 유럽 사업과 입지를 확대하고 글로벌 전문 프랜차이즈를 발전시킨다는 전략에 따라 혁신적인 안과 건강 제품을 다양하게 보유하고 있고 판로도 확실한 비쥬파마를 인수했다. 루팡은 비쥬파마의 기존 영업망을 흡수해 전 세계 인구 고령화, 당뇨병 관련 안과 합병증 발생률 상승, 예방 치료에 대한 인식 증가에 따라 전 세계적으로 크게 성장하고 있는 안과 시장을 공략할 계획이다. 루팡은 비쥬파마의 유럽 영업망을 이용하면 이탈리아, 영국, 스페인, 독일, 프랑스 등 주요 유럽 국가에서 시장을 확대하고 입지를 강화하는 한편 사업도 다각화할 수 있을
[ 메디채널 김갑성 기자 ] - Reinforcing Commitment to Preventive Cardiovascular and Home Blood Pressure Monitoring - KYOTO, Japan, Sept. 29, 2025 -- OMRON HEALTHCARE Co., Ltd., a global leader in innovative medical equipment for preventive healthcare, announced that cumulative worldwide sales of OMRON blood pressure monitors (BPMs) have exceeded 400 million units. This landmark achievement underscores the company's longstanding commitment to extending healthy life expectancy by advancing home blood pressure monitoring and preventive cardiovascular care. Logo: https://cdn.kyodonewsprwire
BANDAR SERI BEGAWAN, Brunei, Sept. 29, 2025 -- Over 2,000 residents across all age groups converged at BIBD Connects, Taman Mahkota Jubli Emas, Bandar Seri Begawan, on 28 September 2025 as the Ministry of Health officially launched a five-month nationwide health campaign aimed at combating sedentary lifestyles and promoting preventive healthcare across the nation. The BN on the Move Championship 2025 will run through February 2026 with monthly challenges and lucky draws designed to sustain participation among the 400,000 Bruneians already using the BruHealth application.
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO Capital Partners LLP (GHO). The acquisition of VISUfarma, with its broad portfolio of innovative eye health products and established commercial infrastructure, aligns with Lupin's strategy to expand its Europea
[ 메디채널 김갑성 기자 ] Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SAN ANTONIO, Sept. 29, 2025 -- Frost & Sullivan is pleased to announce that Viva Biotech has been given the 2025 APAC Technology Innovation Leadership recognition in the Integrated Intelligent Drug Discovery industry for its outstanding achievements in driving transformative efficiencies in preclinical research and development. This recognition highlights Viva B
BANGKOK, Sept. 29, 2025 -- Chula ARi, an interdisciplinary initiative by Chulalongkorn University, addresses the challenges of Thailand's rapidly aging society by using research to develop comprehensive elderly care models across economic, social, health, environmental, and innovation dimensions. The project also encourages pre-senior citizens to prepare for future aging challenges. Thailand is approaching a "senior tsunami," with the population aged 60 and above expected to rise from 20% to 30% within the next decade, transforming the nation into a super-aged society
[ 메디채널 김갑성 기자 ] 방콕 2025년 9월 29일 -- 쭐랄롱꼰 대학교가 추진하는 학제 간 이니셔티브인 쭐라 ARi(Chula ARi)는 고령화 사회로 빠르게 진입하고 있는 태국이 직면한 다양한 과제를 해결하기 위해 경제, 사회, 건강, 환경, 혁신 차원을 아우르는 포괄적인 노인 돌봄 모델 개발을 위한 연구를 진행하고 있다. 이 프로젝트는 또한 고령화로 인해 예비 고령층이 미래에 겪게 될 문제에 대비할 수 있도록 장려한다. 태국은 향후 10년 이내 60세 이상 인구 비율이 현재의 20%에서 30%로 올라가며 초고령 사회에 진입할 것으로 예상된다. 즉 '고령화 쓰나미(senior tsunami)'가 몰려오게 되는 것이다. 쭐라 ARi 책임자인 비판 프라추암모(Vipan Prachuabmoh) 교수(박사)는 1963~1983년 사이에 태어난 대규모 인구 집단이 매년 약 100만 명씩 신규 고령층으로 편입된다는 점을 지적한다. 이들의 기대 수명은 길어졌지만, 만성 질환에 걸리거나 의존이 필요한 사람이 증가하면서 사회•복지적 부담이 커지고 있다는 설명이다. 2018년 C2F 기금으로 출범한 쭐라 ARi는 태국 노인